<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68879">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986140</url>
  </required_header>
  <id_info>
    <org_study_id>H: 33692 SCALP</org_study_id>
    <nct_id>NCT01986140</nct_id>
  </id_info>
  <brief_title>Scalp Cooling to Prevent Chemo-induced Hair Loss</brief_title>
  <acronym>SCALP</acronym>
  <official_title>Scalp Cooling for Alopecia Prevention (SCALP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Breast Care Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in
      reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or
      adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cooling the scalp during chemotherapy may help reduce the chances of losing hair during
      treatment.  The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device
      may stop patients who are undergoing chemotherapy from losing their hair.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>4 to 8 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint will be success in hair preservation, defined as CTCAE v 4 alopecia grade &lt;2, and will be assessed by a healthcare professional who is blinded to study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A safety follow-up for safety data will be done yearly for 5 years looking at time to first recurrence of breast cancer, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. This will be collected during routine clinical observation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improved Quality of Life</measure>
    <time_frame>4 to 8 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improved quality of life as a result of reduced hair loss is a primary motivator for developing the Paxman Scalp Cooling device. Quality of life will be assessed at baseline and 2-3 weeks after each course of chemotherapy. Three widely used and validated scales will be used: the EORTC QLQ C-30, HADS and BIS. Subjects will be evaluated at multiple time points and data will be analyzed using descriptive methods with median and inter quartile rang to assess the effect of treatment group and alopecia status on functioning, quality of life and depression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>Scalp Cooling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scalp Cooling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAXMAN Orbis Scalp Cooler</intervention_name>
    <description>Treatment with Orbis scalp cooling cap</description>
    <arm_group_label>Scalp Cooling</arm_group_label>
    <other_name>PAXMAN Orbis Scalp Cooler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control No treatment to prevent hair loss</intervention_name>
    <description>No treatment to prevent hair loss</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>No intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnosis of breast cancer stage 1-2

          -  Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent

          -  Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline or
             taxane based chemotherapy regimen,

          -  Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide
             600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Paclitaxel
             80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3
             weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2
             with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and
             trastuzumab at standard doses

          -  Trastuzumab at standard doses is allowed in combination with taxane based
             chemotherapy

          -  Administration of chemotherapy on a dose dense schedule is allowed as clinically
             indicated.

        Exclusion Criteria:

          -  Stage 3 or 4 breast cancer or any other concurrent malignancy including hematological
             malignancies (i.e. leukemia or lymphoma)

          -  Baseline alopecia (defined CTCAE v4.0 grade &gt; 0, see appendix B for CTCAE v4.0 scale)

          -  Subjects with cold agglutinin disease or cold urticaria

          -  Subjects who are scheduled for bone marrow ablation chemotherapy

          -  Subjects receiving chemotherapy with concurrent anthracycline and taxane (AT or TAC)

          -  Male gender
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Nangia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Otte</last_name>
    <phone>713-798-1999</phone>
    <email>kristen.otte@bcm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudette Foreman</last_name>
    <phone>713-798-7315</phone>
    <email>caforema@bcm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology &amp; Oncology Associates of Northern New Jersey</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-538-3593</phone>
      <phone_ext>2338</phone_ext>
      <email>mmackenzie@hoannj.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Fritsch</last_name>
      <phone>973-538-3593</phone>
      <email>kfritsch@hoannj.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Papish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurel Andrews</last_name>
      <phone>214-370-1000</phone>
      <email>lori.andrews@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Francis Collins</last_name>
      <phone>(214)370-1000</phone>
      <email>francis.collins@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cyntiha Osborne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lester and Sue Smith Breast Center at Baylor College of Medicie</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Otte, BS</last_name>
      <phone>713-798-1999</phone>
      <email>Kristen.Otte@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Reusser, BA</last_name>
      <phone>713-798-1929</phone>
      <email>breusser@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Polly Niravath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mothaffar Rimawi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kent Osborne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mari Rude, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sao Jiralerspong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOncology / Texas Oncology-Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amber Mendoza</last_name>
      <phone>713-467-1722</phone>
      <email>amber.mendoza@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Renard</last_name>
      <phone>713-467-1722</phone>
      <email>jamie.renard@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frankie Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Alopecia</keyword>
  <keyword>Scalp</keyword>
  <keyword>Cooling</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
